V85546
Summary
V85546 is a selective MMP 12 (macrophage elastase) inhibitor which has been developed by Serono under a collaboration initiated in 2000. Following the merger of Serono with Merck KGA exclusive worldwide rights to the MMPI programme have been reacquired by Vernalis. V85546 has completed Phase I studies and is supported by an extensive pre-clinical toxicology and pharmacology package. There are several high value potential indications for V85546, including COPD, MS and rheumatoid arthritis and Vernalis is determining the optimal indication in which to take it forward. In addition to the lead molecule, there is also a back-up candidate ready to enter pre-clinical development. It is likely that further development would be conducted in collaboration with a partner, although options for adding value by conducting a focussed proof-of-concept study in one or more indications are being evaluated.
